We are very excited to introduce the Humanized IgG Göttingen Minipigs, a genetically altered Göttingen Minipigs strain carrying a mini repertoire of human genes for the immunoglobulin heavy chains γ1 and γ4 and the immunoglobulin light chain κ.
Genetically altered Göttingen Minipigs show tolerance to a broad range of human antibodies. This provides a novel model for safety testing and an important and viable alternative for toxicology studies of therapeutic antibodies in non-human primates.
Testing of human therapeutic antibodies can be challenging
It can be challenging to test human therapeutic antibodies in vivo due to xeno responses, resulting in rapid clearance or toxicity.
“Humanized IgG Göttingen Minipigs have the ability to predict adverse outcomes of therapeutic antibodies (true anti-drug antibody reactions), and the Humanized IgG Göttingen Minipigs can enhance preclinical safety predictions for this important class of drugs,” says Andres Eskjær Jensen, Study Director at Ellegaard Göttingen Minipigs A/S.
As stated by Martin Windfeld Velin, CEO at Ellegaard Göttingen Minipigs A/S, this genetically altered Göttingen Minipigs model is yet another step, through which we pursue our goal of enabling the development of safer and more effective medicines and treatments, and we are excited about new collaborations and projects based on this large animal model in the years to come.
If you are interested to learn more about the Humanized IgG Göttingen Minipigs, please join our exhibitor hosted session at SOT on March 21, 13.30 – 14.30 pm, room 101C.
Topic: Göttingen Minipigs in Preclinical Toxicology - Current Trends and Humanized lgG Göttingen Minipigs
For more information on the Humanized IgG Göttingen Minipigs, please contact Study Director Andres Eskjær Jensen at Ellegaard Göttingen Minipigs A/S;
cell phone: +45 22 51 91 79 or e-mail: aej@minipigs.dk